- Chief Executive Officer Dr. Keith Ward will discuss Kuria's development of novel Nrf2 activators to power sight
Kuria Therapeutics, a pharmaceutical company developing a platform of novel Nrf2 activators for ophthalmic disease, has been selected for participation in the Ophthalmology Futures European Forum in Vienna, Austria. Kuria's Chief Executive Officer, Dr. Keith Ward, will appear via a recorded presentation to share Kuria's mission and development progress. Dr. Ward's presentation will be shown at 11:26 am CET on Thursday, 07 September 2023 at the meeting in the Hilton Danube Waterfront Hotel in Vienna, and will also be made available on the Kuria website.
Watch the video below
About Kuria Therapeutics, Inc.: Kuria Therapeutics, Inc. is a US-based pharmaceutical company dedicated to the development of novel therapeutics for ophthalmic disease. We are a team of seasoned life science executives and entrepreneurs with decades of experience in building biotechnology companies, running complex multi-national development programs, managing alliances with partners, and building relationships with clinicians, investors, vendors, and patient groups. For more information, visit www.kuriatx.com.
Contacts
Investor Relations and Media
Kuria Therapeutics:
Corporate Communication
info@kuriatx.com
Kommentare